 vivo platelet activation beta-thalassemia major increased platelet-thromboxane urinary metabolites frequency thromboembolic events patients beta-thalassemia major TM Platelet function anomalies impaired aggregation aggregates finding shortened platelet survival platelets hypercoagulability thalassemia technique thin layer chromatography purification immunoassay urinary metabolites thromboxane prostacyclin splenectomized patients beta-TM non-splenectomized patients beta-thalassemia intermedia TI healthy individuals significant increase urinary excretion alpha patients TM TI healthy controls significant differences concentrations metabolites TM TI patients Six TM patients low dose aspirin mg/day days significant decrease urinary concentrations platelets levels urinary alpha vascular production alpha kidney results consistent vivo production endogenous platelet activation